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doi:10.1016/j.ejvs.2009.07.007Abstract The International Carotid Stenting Study (ICSS) and an amalgamated ‘super’
Registry of ‘high risk for surgery’ patients undergoing carotid artery stenting (CAS) have issued
seemingly contradictory conclusions following release of their 30-day procedural risks. This
paper evaluates the impact of the two trials, regarding the current status of CAS, and
concludes that there are still more questions than answers.
The available evidence supports CAS in the treatment of selected ‘high risk for CEA’ non-octoge-
narian symptomatic patients, provided certain caveats are met (maintenance of acceptable proce-
dural risk, rapid intervention). There is, however, no level I evidence supporting the routine use of
CAS in ‘standard risk’ symptomaticpatients and thisCochrane recommendationwill not changeonce
the ICSS data are included. It is anticipated, however, that following meta-analyses of individual
patientdata from5000patients recruited into the four large, randomised trials (SPACE, EVA-3S, ICSS,
CREST), selected patient subgroups will be identified who will benefit by being treated by CAS.
In the meantime, the majority of standard risk, symptomatic patients should probably undergo
expedited CEA. However, established (or less experienced) practitioners who intend to continue
offering CAS to this category of patient (because it is already approved practice in their health
system) must ensure that their audited 30-day risks of death/stroke remain<6% and that they offer
patients access to expedited intervention (iewithin 2 weeks) wherever possible. Delaying interven-
tion in order to reduce the procedural risk may improve the reputation of the surgeon/interven-
tionist, but it confers little overall benefit to the patient.
ª 2009 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.‘‘It is better to know some of the questions than all of
the answers’’
James Thurber (1894e1961)16 2523179.
.nhs.uk
ty for Vascular Surgery. PublisheA number of randomised trials, comparing carotid
endarterectomy (CEA) with carotid artery stenting (CAS),
have released data detailing long term freedom from
stroke. Without exception, each reported that following
successful stenting (ie assuming no strokes or deaths in the
first 30-days), CAS was as durable as CEA.1e4 This finding is
important to document as many observers had anticipatedd by Elsevier Ltd. All rights reserved.
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translate into an increased risk of late stroke. Accordingly,
the key issue to be resolved is the 30-day risk of death/
stroke, as this is likely to determine which procedure will
remain (or become) the ‘gold standard’. In this respect,
CAVATAS observed no difference in the procedural risk
between CEA and CAS,1 SPACE reported that although CAS
failed to prove ‘non-inferiority’, CEA was not statistically
superior,2 while EVA-3S found that CAS was statistically
inferior.3 Notwithstanding a number of methodological
criticisms (invariably made after a trial has reported rather
than at its inception), the 2009 Cochrane Review concluded
that CEA should remain the first line intervention in ‘stan-
dard’ risk, symptomatic patients.5 This decision is not
unreasonable given that recent data from the US National
Inpatient Sample reported significantly higher procedural
risks (especially in symptomatic patients) following CAS.6,7
Accordingly, in view of the complex and occasionally
turbulent recent history, the extent of corporate invest-
ment and those still unresolved ‘turf-wars’, it was inevi-
table that when two influential studies released conflicting
30-day outcomes, the prospect of achieving consensus
seemed remote. The first to release their 30-day data was
the International Carotid Stenting Study (ICSS), now the
largest randomised trial comparing CEA with CAS in 1710
recently symptomatic patients recruited from 50 centres in
15 countries from Europe, Canada, Australia and New
Zealand.8 Contrary to their earlier experience with CAV-
ATAS, ICSS now reported that patients randomised to CEA
had a significantly lower procedural risk than patients
randomised to CAS (8.5% after CAS vs 5.1% after CEA,
ARRZ 3.4%, pZ 0.004). In addition, a subgroup of ICSS
patients who underwent serial MRI imaging had signifi-
cantly more early and (ultimately) persisting new ischae-
mic brain lesions following CAS (despite cerebral
protection) than after CEA. In his address to the 2009
European Stroke Conference,8 Professor Martin Brown (ICSS
Principle Investigator) observed that ICSS had ‘‘provided
strong evidence that CEA was safer than CAS in the primary
intention to treat analysis and also in the per-protocol
analysis, where twice as many strokes were associated
with stenting as with endarterectomy’’, concluding that
‘‘carotid endarterectomy was still the treatment of choice
for suitable patients with a recently symptomatic carotid
artery stenosis.’’
The cardiovascular community had relatively little time
to absorb these important data when a ‘super’ Registry of
CAS patients (recruited to post-marketing surveillance in
the EXACT and CAPTURE ‘high risk for CEA’ Registries)
reported 30-day outcomes.9 Within a cohort of 6320
patients, 761 (12%) had suffered a stroke/TIA in the 6
months prior to CAS, ie similar to the definition of ‘recently
symptomatic’ used in ICSS. The combined Registry then
performed subgroup analyses in their symptomatic
patients, stratified for age. The 30-day rate of death/stroke
in 589 patients aged <80 years was 5.3% (95%CI 3.6e7.4%),
while the 30-day risk of death/stroke in 172 patients aged
>80 years was 10.5% (95%CI 3.3e16%). The authors
concluded that ‘‘CAS outcomes had improved in non-octo-
genarian, high surgical risk patients since the pivotal Food
and Drug Administration approval trials’’ and that ‘‘CAS
had demonstrated real-world outcomes consistent withestablished American Heart Association (AHA) guidelines in
symptomatic patients’’.
To any uncritical observer, it might seem that the
amalgamated Registry was reporting paradoxically better
outcomes for CAS in ‘high risk’ patients than for CAS
patients in a randomised trial that only recruited ‘standard
risk subjects’. So, how should these data be interpreted
and how might they influence practice, especially while we
await publication of CREST? The publication of CREST in
2010 is likely to be pivotal in determining future practice,
not just because it is the final, large-scale randomised trial
to report, but mainly because there has sometimes been
a tendency to simply dismiss CAS results from the European
randomised trials as being somehow inferior to current CAS
practice in the United States.10 It should, therefore, come
as no surprise that much of the debate has been mired in
dogma, methodological criticism, conflicts of interest amid
unspoken concerns about threats to professional influence
and income (on both sides of the debate). As a conse-
quence, it can be very difficult to remain focussed on the
critical issue; ie the prevention of stroke. Accordingly, now
would seem a good time for everyone to take a step back
and remember Thurber’s counsel; ‘‘It is better to know
some of the questions than all of the answers’’. This is
because in order to plan a pragmatic appraisal about how to
develop optimal practice for the future, we have to balance
what ICSS and the amalgamated Registry have told us with
what they have not!
The first question posed by the Registry data is whether
there is now sufficient evidence to recommend CAS in
patients aged <80 years who might otherwise be deemed
‘high risk for CEA’? Recent history suggests that there will
be polarised opinions about what actually constitutes being
‘high risk for CEA’, but on the basis of the amalgamated
Registry (which used the same definition of ‘recently
symptomatic’ as ICSS and required independent neurolog-
ical assessment at 24 h and 30-days) the answer is a quali-
fied ‘yes’. There are, however, important caveats to this
recommendation. First, the low procedural risk observed in
non-octogenarian patients in the amalgamated Registry
must be maintained and regularly audited. If it exceeds 8%,
it is unlikely that any long term benefit will accrue to the
patient and the interventionist should review his/her
selection criteria. Second, is a request that interventionists
recognise that the magnitude of benefit conferred to the
patient (in terms of late stroke prevention) will be signifi-
cantly increased if their interventions are primarily
undertaken in patients who also present with criteria that
make them ‘high risk for stroke’. These criteria include;
male gender, patients with hemispheric rather than retinal
symptoms, increasing medical co-morbidity, very recent
symptoms, more severe degrees of stenosis (ie not 50e69%
or those with subocclusion) and contralateral occlusion.11
Clearly, there is also a separate issue about how best to
manage the ‘high risk for CEA’ patient who is aged >80
years. This was not specifically addressed by the Registry,
possibly because the procedural risk exceeded 10%, ie
exceeding the AHA threshold. However, NASCET has shown
that symptomatic patients aged >75 years gained greater
benefit from CEA than any other patient age-group.12
Accordingly, if after clinical review, the elderly ‘high risk
for CEA’ patient also exhibited features that made them
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99% as opposed to 50e69% stenoses, contralateral occlu-
sion), it might still be reasonable to offer CAS despite there
being the potential for incurring a slightly higher procedural
risk than their younger counterparts. However, if the risk
exceeds 10%, it is again unlikely that any long term benefit
will accrue to the patient. Each case must, therefore, be
considered on its merits and some recently symptomatic
patients aged >80 years should, perhaps, be reconsidered
for CEA or treated conservatively.
One final consideration regarding the ‘high risk for CEA’
patient, is whether the 30-day risks after CAS vary
according to whether the patient had primary atheroscle-
rotic disease or non-atherosclerotic disease (eg radiation
arteritis, restenosis after CEA, etc). In many of the ‘high
risk’ Registries published to-date, up to 40% of patients had
restenosis after CEA. Although this is likely to be more of
a confounding factor in asymptomatic patients, secondary
analyses from the ARCHeR CAS Registry showed that the
30-day risk following CAS in patients with non-atheroscle-
rotic disease was 14 times lower in patients with non-
atherosclerotic disease (overall riskZ 6.6%, but 0.7% in
non-atherosclerotic patients vs 9.5% in patients with
atherosclerosis).13 It would, therefore, be helpful if the
Registries now provided separate outcome data for patients
with atherosclerotic and non-atherosclerotic disease,
especially in those studies where the proportion of patients
with the latter pathology exceeded 25%.
The next question to be addressed is; ‘‘why have there
been much lauded reductions in the procedural risk after
CAS in non-randomised, observational studies but no
apparent improvement in the 30-day risk of death/stroke
after CAS in randomised trials undertaken in the decade
after CAVATAS?’’1e3 This is, of course, no different to
comments levelled at surgeons by neurologists in the
1980s and early 1990s. In 2001, CAVATAS was heavily
criticised for the high procedural risk after both CEA and
CAS. However, while the 30-day risk after CEA improved
from the 9.9% observed in CAVATAS (SPACEZ 6.3%,
EVA-3SZ 3.9%, ICSSZ 5.1%), the same does not apply to
CAS (CAVATASZ 10.0%, SPACEZ 6.8%, EVA-3SZ 9.6%,
ICSSZ 8.5%).
Commentators have raised a number of methodological
criticisms regarding CAS practice in each of these trials
(interventionist experience, use of protection devices), but
the reality is that that numerous factors are likely to be
responsible for the excess risk of procedural stroke
observed in ICSS and the other randomised trials. Guidance
for the less experienced CAS practitioner (regarding
adverse anatomic features) has been provided in a practical
and helpful Delphi Consensus statement,14 but the combi-
nation of the SPACE, EVA-3S and ICSS databases (plus CREST
in due course) should permit meaningful individual patient
meta-analyses to be performed on approximately 5000
patients. This will enable factors such as time from symp-
toms to intervention, presenting symptoms, medical
co-morbidity, patient selection criteria, interventionist
experience, use of protection devices, stent types, gender,
age and many other parameters to be evaluated in order to
identify cohorts of recently symptomatic patients who are
predicted to be either high or low risk for suffering
a procedural stroke after CAS.The next (and perhaps most important question) is
whether rapid intervention influences the early procedural
risk? When ICSS and EXACT/CAPTURE started to recruit
their patients, the definition of ‘recently symptomatic’ was
any ipsilateral carotid territory symptom occurring within
the preceding 6 months, ie in line with the definition used
in ECST and NASCET. However, the world of stroke
prevention has now moved on and this ‘one size fits all’
concept is overly simplistic and should be considered
obsolete.
There is now indisputable evidence that the risk of
stroke (after a TIA/minor stroke) is much higher than was
previously thought, with the highest risk period being the
first seven days after onset of symptoms. In addition, there
is compelling evidence that any delay to intervention
rapidly diminishes the benefit accruing to the patient.14 For
example, if the delay to intervention exceeds 12 weeks,
only 8 strokes will be prevented at five years by performing
1000 CEAs in patients with 50e99% NASCET stenoses.15 As
a consequence, health systems around the world are now
radically changing practice so that TIA patients are inves-
tigated and treated with the same urgency and priority as
patients with myocardial infarction. In the UK, this has
translated into a NICE recommendation that all patients
should be treated within two weeks of onset of symp-
toms,16 while the UK Government would prefer this
threshold to be reduced to 48 h.17
Accordingly, the CAS Registries and any future meta-
analyses of the randomised trials must go back and evaluate
the relationship between the time from onset of symptoms
to treatment and then specifically relate this to the
procedural risk. It is no longer acceptable to simply provide
outcome risk data for patients who were treated within 6
months of onset of symptoms. In that way, we will be better
informed as to what might become the preferred inter-
vention (CEA or CAS) in patients who are being treated
within 7 or 14 days of onset of symptoms. This could mean,
of course, that one intervention might be safer (and more
generalisable) in the ‘hyper acute’ phase of treatment,
while the other might be preferable after some time has
elapsed. The importance of addressing this question was
highlighted by two recent CAS studies and one surgical
audit. In a 2007 subgroup analysis from the CAPTURE CAS
Registry,18 it was reported that the 30-day risk of death/
stroke was 2.5 times higher if CAS was performed within
two weeks of the most recent symptom (pZ<0.05). After
four weeks, there was no difference in procedural risk. In
EVA-3S, 20% of patients randomised to CAS underwent
treatment within 14 days of onset of symptoms and showed
a trend towards a higher procedural risk.19 Similarly,
expedited CEA (performed within 4 weeks of symptom
onset) was found to almost triple the 30-day risk in symp-
tomatic patients in a large single centre series from New
York.20
When clinicians were previously faced with evidence
suggesting that early intervention increased the procedural
risk, the natural response was to accept (possibly
encourage) an element of delay within the patient pathway
(thereby making the surgeon/interventionist look good, but
at the patient’s expense). In the ‘new world’, this should
not be accepted to represent optimal practice. Contrary to
an intuitively held belief that a higher initial procedural risk
400 A.R. Naylornegates any long term benefit, data from the Carotid
Endarterectomy Trialists Collaboration suggest that
a surgeon (or interventionist) who operates with a 10%
procedural risk within 2 weeks of onset of symptoms will
still prevent more strokes in the long term than a surgeon
who defers any intervention for >4 weeks and then oper-
ates with a 0% procedural risk.15 Establishing whether there
is a significant relationship between delay to CEA or CAS
and increased procedural risk is one of the most important
issues still to be evaluated in the CAS Registries and any
future meta-analyses of the randomised trials.
The final (and inevitable) question following release of
the ICSS data is how ‘standard risk’ symptomatic patients
should be treated pending CREST’s publication? Clearly,
practice will vary among different countries and health
systems where the routine use of CAS may already be
considered acceptable. In established, high volume CAS
centres that already treat ‘standard risk’ symptomatic
patients, it would seem reasonable to continue offering this
service provided that; (i) the 30-day risk of death/stroke
is independently audited and maintained <6% and
(ii) patients are treated without delay, preferably within 14
days. If these two caveats cannot be achieved, the patient
should be referred for expedited surgery.
By contrast, centres with limited or no CAS experience
face a more difficult decision. None of the randomised
trials currently support the preferential use of CAS (over
CEA) in standard risk, symptomatic patients and the 2009
Cochrane Review (prepared prior to the release of the ICSS
data) continues to recommend CEA as the first line option.5
This recommendation will obviously not change when the
ICSS data are included. Accordingly, the simplest advice
might be to avoid CAS in these patients until CREST has
reported and individual patient meta-analyses have iden-
tified patient subgroups who should be treated by CAS (eg
perhaps the younger, recently symptomatic patient as
proposed by SPACE21). If, however, a vascular surgeon or
interventionist still felt compelled to expand their CAS
practice in standard risk, symptomatic patients, they are
legally (and morally) required to adhere to the two caveats
required of their more experienced CAS colleagues (ie low
audited risks and rapid intervention). Provided these
caveats are met, it is unlikely that their practice can be
criticised. If these criteria cannot be met, patients should
be referred for expedited CEA. Remember, delay generally
benefits no-one apart from the surgeon or interventionists
reputation.
Finally, anyone considering expanding their CAS practice
into treating standard risk, symptomatic patients (despite
the lack of level I evidence) should exercise caution
regarding limiting their potential exposure to medico-legal
censure during the inevitable ‘learning curve’, ie the less
experienced CAS practitioner must take responsibility for
being comprehensively mentored in large, established
centres until they are capable of performing CAS within two
weeks of symptom onset and within the 6% threshold of
risk. Evidence suggests that about 50 CAS procedures
currently constitutes the average learning curve21 and, as
part of the informed consent process, it is a legal require-
ment of the less experienced CAS practitioner (and vascular
surgeon) to inform the patient of the degree of experience
he/she currently has.22 As was presciently stated by Healey& Samanta in their 2008 Masterclass in response to the
question ‘‘when does a learning curve become question-
able practice’’,23 ‘‘the relative inexperience of a surgeon
(interventionist) embarking upon a learning curve might
seriously impact upon the outcome. Arguably this risk is
material and therefore subject to disclosure in the law’’. In
this situation where there is currently no level I evidence to
support intervention by CAS in standard risk, symptomatic
patients, this might be considered by many to be taking one
risk too far for the less experienced interventionist.Conflict of Interest
None.
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